Analysis updated on Oct. 16, 2026 (UTC) · Total · absolute moveSwitch to Alpha · Nasdaq
Our AI ranks Fulgent Genetics, Inc. outside the neutral middle of its coverage (a directional signal). Create a free account and follow it to see the exact price target.
Fulgent Genetics, Inc. is a small-cap company with a market capitalization of $545M. It ranks number 17 by market capitalization among the 29 Services-Medical Laboratories issuers in our coverage with a current forecast.
For FLGT, the Spearman rank correlation between our 90-day forecasts and the returns that followed is 47.0%, measured on 357 forecast dates between 2022-07-29 and 2026-07-17 on this stock's own recent history. A rank correlation runs from -100% to +100%: it measures whether higher forecasts were followed by higher returns, and a value near zero or below means the model has shown little skill on this stock. On the 30-day forecasts the same correlation is 32.0%, measured on 400 forecast dates between 2022-07-29 and 2026-09-16. Across our coverage, the out-of-sample test on 4495 stocks from 2025-01-06 to 2026-07-07 produced a positive net return in 82.5% of rebalance periods (factor-neutral book, net of estimated costs). Full backtest report
Expected absolute price move over the horizon, market included. This is the number a price target is built from. Ratings: strong buy ≥ +5.1%, buy ≥ +3.4%, sell < +1.8%, strong sell < +0.8% (top 15%, next 20%, middle 30%, next 20%, bottom 15% of the 2026-10-16 signals)
A free account shows the exact forecast, rating and rank of 3 tickers you follow, FLGT included.
Follow FLGT free90D Total forecasts of every company scored, cut into five relative ratings at the 15th, 35th, 65th and 85th percentiles (dashed lines).
Trailing twelve months. The industry median and the rank (1 = highest) are taken over the Services-Medical Laboratories peers listed below that report each metric.
| Metric | FLGT | Rank |
|---|---|---|
| Market Cap | $545M | 17/29 |
| P/B Ratio | 0.54x | 19/22 |
| EPS | $-3.20 | – |
| Book Value/Share | $36.40 | – |
| Revenue/Share | $11.77 | – |
| FCF/Share | $-3.77 | – |
| Metric | FLGT | Rank |
|---|---|---|
| ROE | -8.4% | 7/14 |
| ROA | -7.8% | 10/20 |
| ROIC | -12.0% | 12/24 |
| Gross Margin | 35.6% | 6/16 |
| Operating Margin | -37.8% | 15/23 |
| Net Margin | -26.1% | 10/17 |
| EBT Margin | -28.5% | 15/23 |
| Tax Rate | 7.5% | – |
| Metric | FLGT | Rank |
|---|---|---|
| Current Ratio | 6.34x | 6/26 |
| Quick Ratio | 6.33x | 3/11 |
| D/E Ratio | 0.09x | 20/22 |
| Financial Leverage | 1.09x | 20/22 |
| Interest Coverage | -751.5x | 20/23 |
| Working Capital | $383M | 10/26 |
| Metric | FLGT | Rank |
|---|---|---|
| Operating Cash Flow | -$84M | 23/27 |
| Free Cash Flow | -$104M | 14/17 |
| Capital Spending | -$20M | 10/17 |
| FCF/Sales | -32.0% | 13/16 |
| CapEx/Sales | 6.2% | 5/16 |
| Metric | FLGT | Rank |
|---|---|---|
| Asset Turnover | 0.30x | 13/18 |
| Receivables Turnover | 5.0x | 15/19 |
| Inventory Turnover | 263.1x | 1/7 |
| Fixed Assets Turnover | 2.9x | 13/17 |
| Days Sales Outstanding | 73 days | 5/19 |
| Days Inventory | 1 days | 7/7 |
| Payables Period | 27 days | 11/14 |
| Cash Conversion Cycle | 47 days | 6/6 |
| Metric | FLGT | Rank |
|---|---|---|
| Total Revenue | $324M | 11/19 |
| Operating Income | -$122M | 22/26 |
| Net Income | -$84M | 15/20 |
| R&D Expense | $57M | 9/20 |
| SG&A Expense | $244M | 10/20 |
| Cost of Goods Sold | $209M | 5/15 |
| Metric | FLGT | Rank |
|---|---|---|
| Shares Outstanding | 28M | – |
| Total Current Assets | $455M | 41.8% of assets |
| Cash & Short-term Investments | $26M | 2.4% of assets |
| Accounts Receivable | $65M | 6.0% of assets |
| Inventory | $790K | 0.1% of assets |
| Total Liabilities | $93M | 8.6% of assets |
| Short-term Debt | $56M | 5.2% of assets |
Companies classified under the same SEC industry code as Fulgent Genetics, Inc. (Services-Medical Laboratories): 30 common-stock issuers with a forecast this week, one row per issuer, largest first. This is a classification match, not a curated list of competitors.
Reveal all forecasts · See exact % predictions for all competitors
Sign up free| Company | 90-Day AI Forecast (Total) | Market Cap |
|---|---|---|
| FLGT Fulgent Genetics, Inc. | ▲ | $545M |
| NTRA Natera, Inc. | ▲ | $56.71B |
| DGX Quest Diagnostics Inc | ▼ | $25.94B |
| LH Labcorp Holdings Inc. | ▼ | $25.79B |
| GH Guardant Health, Inc. | ▲ | $21.28B |
| CAI Caris Life Sciences, Inc. | ▲ | $8.64B |
| RDNT Radnet, Inc. | ▶ | $5.41B |
| GRAL Grail, Inc. | ▲ | $5.26B |
| BLLN Billiontoone, Inc. | ▲ | $4.63B |
| VCYT Veracyte, Inc. | ▲ | $3.47B |
| CDNA Caredx, Inc. | ▲ | $3.31B |
| CELC Celcuity Inc. | ▲ | $2.77B |
| FTRE Fortrea Holdings Inc. | ▲ | $2.14B |
| PSNL Personalis, Inc. | ▲ | $1.67B |
| FRNM Freenome, Inc. | ▶ | $1.26B |
| LMRI Lumexa Imaging Holdings, Inc. | ▶ | $1.04B |
| CSTL Castle Biosciences Inc | ▲ | $976M |
| BDSX Biodesix Inc | ▲ | $250M |
| XGN Exagen Inc. | ▲ | $187M |
| BNR Burning Rock Biotech Ltd | ▲ | $139M |
| SERA Sera Prognostics, Inc. | ▼ | $80M |
| CFOR Capforce Inc. | ▲ | $43M |
| MDXH Mdxhealth Sa | ▲ | $20M |
| AMS American Shared Hospital Services | ▼ | $9M |
| ADVB Advanced Biomed Inc. | ▼ | $7M |
| ACON Aclarion, Inc. | ▲ | $5M |
| BGLC Bionexus Gene Lab Corp | ▲ | $4M |
| LUDG Ludwig Enterprises, Inc. | ▼ | $670K |
| FCHS First Choice Healthcare Solutions, Inc. | ▼ | $260K |
| RNLXY Renalytix Plc | ▶ | N/A |
Good morning, and welcome to the Fulgent Fourth Quarter and Fiscal Year 2025 Financial Results Conference Call. On the call are Ming Hsieh, Chief Executive Officer; Paul Kim, Chief Financial Officer; ...
The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...
Fulgent Genetics, Inc. (NASDAQ: FLGT) (“Fulgent” or the “Company”), a technology-based company with a well-established laboratory services business and a therapeutic development business, today ...
Our AI ranks Fulgent Genetics, Inc. outside the neutral middle of its coverage (a directional signal). Create a free account and follow it to see the exact price target.
For FLGT, the Spearman rank correlation between our 90-day forecasts and the returns that followed is 47.0%, measured on 357 forecast dates between 2022-07-29 and 2026-07-17 on this stock's own recent history. A rank correlation runs from -100% to +100%: it measures whether higher forecasts were followed by higher returns, and a value near zero or below means the model has shown little skill on this stock. On the 30-day forecasts the same correlation is 32.0%, measured on 400 forecast dates between 2022-07-29 and 2026-09-16. Across our coverage, the out-of-sample test on 4495 stocks from 2025-01-06 to 2026-07-07 produced a positive net return in 82.5% of rebalance periods (factor-neutral book, net of estimated costs). Full backtest report
Fulgent Genetics, Inc. forecasts are refreshed on trading days as the daily model run completes. The forecast on this page was produced on Oct. 16, 2026.
30 issuers in our coverage, FLGT included, share the SEC industry code Services-Medical Laboratories. The largest are: Natera, Inc. (NTRA), Quest Diagnostics Inc (DGX), Labcorp Holdings Inc. (LH), Guardant Health, Inc. (GH), Caris Life Sciences, Inc. (CAI), Radnet, Inc. (RDNT).
This analysis is generated automatically using our proprietary AI systems and should not be considered personalized investment advice. Past performance does not guarantee future results. Always conduct your own research and consider consulting a financial advisor before making investment decisions.
Signals, companies, plans: answered from live data.
I read Intratio's daily model signals, company data and your account to answer in seconds, in your language.